NASDAQ:OPNT - Opiant Pharmaceuticals Stock Price, News & Analysis

$15.04
+0.32 (+2.17 %)
(As of 08/19/2019 10:01 AM ET)
Today's Range
$14.72
Now: $15.04
$15.11
50-Day Range
$11.60
MA: $13.14
$15.72
52-Week Range
$9.98
Now: $15.04
$29.55
Volume4,882 shs
Average Volume28,229 shs
Market Capitalization$60.76 million
P/E RatioN/A
Dividend YieldN/A
Beta0.43
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine. Read More…

Industry, Sector and Symbol

Industry Metal mining
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OPNT
CUSIPN/A
Phone310-598-5410

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$13.98 million
Book Value$4.96 per share

Profitability

Net Income$-21,190,000.00

Miscellaneous

Employees16
Market Cap$60.76 million
Next Earnings Date11/6/2019 (Estimated)
OptionableNot Optionable

Receive OPNT News and Ratings via Email

Sign-up to receive the latest news and ratings for OPNT and its competitors with MarketBeat's FREE daily newsletter.


Opiant Pharmaceuticals (NASDAQ:OPNT) Frequently Asked Questions

What is Opiant Pharmaceuticals' stock symbol?

Opiant Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPNT."

How were Opiant Pharmaceuticals' earnings last quarter?

Opiant Pharmaceuticals Inc (NASDAQ:OPNT) posted its earnings results on Thursday, August, 8th. The technology company reported $0.31 earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.55) by $0.86. The technology company earned $6.78 million during the quarter, compared to the consensus estimate of $3.91 million. Opiant Pharmaceuticals had a negative return on equity of 12.74% and a negative net margin of 11.78%. View Opiant Pharmaceuticals' Earnings History.

When is Opiant Pharmaceuticals' next earnings date?

Opiant Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Opiant Pharmaceuticals.

What price target have analysts set for OPNT?

2 brokers have issued 1 year target prices for Opiant Pharmaceuticals' shares. Their forecasts range from $42.00 to $42.00. On average, they anticipate Opiant Pharmaceuticals' stock price to reach $42.00 in the next twelve months. This suggests a possible upside of 179.3% from the stock's current price. View Analyst Price Targets for Opiant Pharmaceuticals.

What is the consensus analysts' recommendation for Opiant Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opiant Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Opiant Pharmaceuticals.

What are Wall Street analysts saying about Opiant Pharmaceuticals stock?

Here are some recent quotes from research analysts about Opiant Pharmaceuticals stock:
  • 1. Northland Securities analysts commented, "We anticipate 2Q royalties from NARCAN of ~$6.165MM. Opiant is slated to report 2Q results post-close on August 8th, and we anticipate a strong topline and bottom line beat." (8/2/2019)
  • 2. Cantor Fitzgerald analysts commented, "We reiterate our OW rating on Opiant, which is developing treatments focused on multiple addictions as well as a new product for opioid overdose. As the company advances its pipeline, and provided the data are positive, which we believe they should be, we expect investors to begin to appreciate the market potential of Opiant’s pipeline, and that should drive the stock higher. Valuation Summary We use a blend of DCF and EV/EBITDA to arrive at our $32 price target." (8/28/2018)

Has Opiant Pharmaceuticals been receiving favorable news coverage?

News articles about OPNT stock have been trending negative recently, according to InfoTrie. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Opiant Pharmaceuticals earned a news sentiment score of -2.3 on InfoTrie's scale. They also assigned media coverage about the technology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Opiant Pharmaceuticals.

Who are some of Opiant Pharmaceuticals' key competitors?

What other stocks do shareholders of Opiant Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Opiant Pharmaceuticals investors own include Cara Therapeutics (CARA), AcelRx Pharmaceuticals (ACRX), Vodafone Group (VOD), Vodafone Group (VOD), Canopy Growth (CGC), Synchrony Financial (SYF), Cronos Group (CRON), Cyberark Software (CYBR), Sangamo Therapeutics (SGMO) and Xilinx (XLNX).

Who are Opiant Pharmaceuticals' key executives?

Opiant Pharmaceuticals' management team includes the folowing people:
  • Dr. Roger Crystal, CEO & Director (Age 43)
  • Mr. David D. O'Toole, Chief Financial Officer (Age 60)
  • Dr. Phil Skolnick, Chief Scientific Officer (Age 72)
  • Mr. Kevin Andrew Pollack Esq., J.D., M.B.A., Advisor (Age 49)
  • Mr. Quan Vu, VP of Corp. Devel.

Who are Opiant Pharmaceuticals' major shareholders?

Opiant Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Stonepine Capital Management LLC (8.04%), Morgan Stanley (0.55%), BlackRock Inc. (0.53%), Granite Investment Partners LLC (0.37%) and Advisor Group Inc. (0.12%). Company insiders that own Opiant Pharmaceuticals stock include Ann L Macdougall, David D O'toole, Geoffrey Wolf, Phil Skolnick, Roger Crystal and Thomas T Thomas. View Institutional Ownership Trends for Opiant Pharmaceuticals.

Which major investors are selling Opiant Pharmaceuticals stock?

OPNT stock was sold by a variety of institutional investors in the last quarter, including Granite Investment Partners LLC. Company insiders that have sold Opiant Pharmaceuticals company stock in the last year include Phil Skolnick and Roger Crystal. View Insider Buying and Selling for Opiant Pharmaceuticals.

Which major investors are buying Opiant Pharmaceuticals stock?

OPNT stock was bought by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Morgan Stanley, BlackRock Inc. and Advisor Group Inc.. Company insiders that have bought Opiant Pharmaceuticals stock in the last two years include Ann L Macdougall and David D O'toole. View Insider Buying and Selling for Opiant Pharmaceuticals.

How do I buy shares of Opiant Pharmaceuticals?

Shares of OPNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Opiant Pharmaceuticals' stock price today?

One share of OPNT stock can currently be purchased for approximately $15.04.

How big of a company is Opiant Pharmaceuticals?

Opiant Pharmaceuticals has a market capitalization of $60.76 million and generates $13.98 million in revenue each year. The technology company earns $-21,190,000.00 in net income (profit) each year or ($7.10) on an earnings per share basis. Opiant Pharmaceuticals employs 16 workers across the globe.View Additional Information About Opiant Pharmaceuticals.

What is Opiant Pharmaceuticals' official website?

The official website for Opiant Pharmaceuticals is http://www.opiant.com/.

How can I contact Opiant Pharmaceuticals?

Opiant Pharmaceuticals' mailing address is 233 WILSHIRE BLVD. SUITE 280, SANTA MONICA CA, 90401. The technology company can be reached via phone at 310-598-5410 or via email at [email protected]


MarketBeat Community Rating for Opiant Pharmaceuticals (NASDAQ OPNT)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  221 (Vote Outperform)
Underperform Votes:  232 (Vote Underperform)
Total Votes:  453
MarketBeat's community ratings are surveys of what our community members think about Opiant Pharmaceuticals and other stocks. Vote "Outperform" if you believe OPNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel